Status:
RECRUITING
Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
Lead Sponsor:
Ruijin Hospital
Conditions:
Esophageal Squamous Cell Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of p...
Eligibility Criteria
Inclusion
- Patients are able to understand and are willing to participate in the trial, and a signed consent form can be obtained;
- Pathologically confirmed esophageal squamous cell carcinoma;
- locally advanced ESCC (cT3-4 or N+);
- the age of patients should be more than 18 years, and less than 80 years;
- aged between 18 and 80 years;
- KPS score of patients should be more than 80
Exclusion
- diagnosis of metastatic esophageal cancer;
- Patient refuses to receive systemic drug treatment;
- clinical diagnosis of pleural metastasis or malignant pleural effusion;
- Pregnant or breastfeeding women;
- Severe non-cancerous medical comorbidities that affect the implementation of radiotherapy.
Key Trial Info
Start Date :
June 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
212 Patients enrolled
Trial Details
Trial ID
NCT06596954
Start Date
June 30 2024
End Date
December 30 2027
Last Update
August 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin hospital, Shanghai jiaotong university school of medicine
Shanghai, China, China, 200025